AI
DMK

Axiom Investors’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Axiom Investors’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,386
Closed -$1.7M – 161
2017
Q1 		$1.7M Buy
+1,386
New +$350K 0.04% 130

Other funds holding DMK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $286M AUM 26.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
SGS
Sterling Global Strategies Carlsbad, California $18M AUM 11.58% 1-Year Est. Return

Axiom Investors's DMK Position: Q2 2017 in Review

Axiom Investors sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2017, closing a stake of 1,386 shares — an estimated $1.7M sold.

Axiom Investors first reported a position in DMK in Q1 2017 and held it in 1 quarter. The position peaked at $1.7M in Q1 2017. 44 funds tracked by Wall St. Rank hold DMK as of Q2 2017.

  • Axiom Investors reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2017 after selling out during the quarter.
  • Axiom Investors sold 1,386 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2017, an estimated $1.7M.
  • Axiom Investors first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q1 2017 and held it in 1 quarter.
  • Axiom Investors's DMK Pharmaceuticals Corporation Common Stock position peaked at $1.7M in Q1 2017.
  • 44 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2017.

Based on Axiom Investors's 13F filing for Q2 2017, filed 14 Aug 2017.